Education
About Us
Working with TipRanks
Follow Us
Affimed (AFMD)
NASDAQ:AFMD
AFMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $8.95
Previous CloseN/A
Volume135.33K
Average Volume (3M)109.43K
Market Cap
$14.23M
Enterprise Value$41.58M
Total Cash (Recent Filing)€4.15M
Total Debt (Recent Filing)€4.80M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
May 21, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding15,227,463
10 Day Avg. Volume103,744
30 Day Avg. Volume109,433
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.00Price Target Upside1082.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Affimed News
PremiumCompany Announcements
Affimed Faces Nasdaq Delisting Risk Due to Share Price
PremiumCompany Announcements
Affimed’s Promising Clinical Update on NSCLC Treatment---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentAffimed’s three active molecules should be of interest to pharma, and a partnership with non-dilutive financing would provide significant support for the stock.
Clinical DataAFMD highlighted positive data from the LuminICE-203 study in cHL, showing significantly higher ORR compared to the only currently available option.
Clinical EfficacyNew AFM24 + atezolizumab data in anti-PD-(L)1 relapsed / refractory EGFRwt non-small cell lung cancer confirm clinical activity and hint at durability of benefit that could translate to a meaningful 'long tail' benefit over cytotoxic-based alternatives.
Bears Say
Financial ConcernsThe initiation of the PTCL cohort in LuminICE-203 is contingent upon securing additional capital.
Funding UncertaintyThere is a 1-1.5 year delay and uncertainty in source of funding for the higher dose strategy.
Price Target AdjustmentThe price target is adjusted from $15 to $11, reflecting updated model assumptions on patient numbers and market penetration.
---
Ownership Overview
―
Insiders
1.45% Mutual Funds
0.85% Other Institutional Investors
97.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AFMD FAQ
What was Affimed’s price range in the past 12 months?
Affimed lowest stock price was $0.52 and its highest was $8.95 in the past 12 months.
What is Affimed’s market cap?
Affimed’s market cap is $14.23M.
When is Affimed’s upcoming earnings report date?
Affimed’s upcoming earnings report date is May 21, 2025 which is in 24 days.
How were Affimed’s earnings last quarter?
Affimed released its earnings results on Mar 27, 2025. The company reported -$0.684 earnings per share for the quarter, beating the consensus estimate of -$0.918 by $0.234.
Is Affimed overvalued?
According to Wall Street analysts Affimed’s price is currently Undervalued.
Does Affimed pay dividends?
Affimed does not currently pay dividends.
What is Affimed’s EPS estimate?
Affimed’s EPS estimate is -0.69.
How many shares outstanding does Affimed have?
Affimed has 15,227,463 shares outstanding.
What happened to Affimed’s price movement after its last earnings report?
Affimed reported an EPS of -$0.684 in its last earnings report, beating expectations of -$0.918. Following the earnings report the stock price went down -3.614%.
Which hedge fund is a major shareholder of Affimed?
Among the largest hedge funds holding Affimed’s share is Baker Bros Advisors LP. It holds Affimed’s shares valued at 0.
---
Company Description
Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
---
AFMD Stock 12 Month Forecast
Average Price Target
$11.00
▲(1082.80% Upside)
Technical Analysis
TherapeuticsMD
―
Aprea Therapeutics
―
Athira Pharma
―
Spruce Biosciences
―
TransCode Therapeutics
―
Best Analysts Covering AFMD
1 Year
1 Year Success Rate
1/20 ratings generated profit
1 Year Average Return
-52.73%
reiterated a buy rating 4 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -52.73% per trade.
---